Wells Fargo & Company Issues Positive Forecast for Crescent Capital BDC (NASDAQ:CCAP) Stock Price

Crescent Capital BDC (NASDAQ:CCAP - Get Free Report) had its target price raised by stock analysts at Wells Fargo & Company from $18.00 to $19.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an "equal weight" rating on the stock. Wells Fargo & Company's price objective would indicate a potential downside of 2.71% from the stock's current price.

Separately, Keefe, Bruyette & Woods lifted their price target on Crescent Capital BDC from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, November 25th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $19.33.

Crescent Capital BDC Trading Up 1.3 %

NASDAQ:CCAP traded up $0.26 on Wednesday, reaching $19.53. The company's stock had a trading volume of 76,316 shares, compared to its average volume of 82,790. The firm has a market cap of $723.82 million, a PE ratio of 7.66 and a beta of 0.81. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.26 and a current ratio of 1.26. The business's 50-day moving average price is $19.38 and its two-hundred day moving average price is $18.77. Crescent Capital BDC has a 1-year low of $15.91 and a 1-year high of $20.03.

Crescent Capital BDC (NASDAQ:CCAP - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.07. The business had revenue of $51.63 million during the quarter, compared to analysts' expectations of $48.76 million. Crescent Capital BDC had a return on equity of 12.20% and a net margin of 47.06%. During the same period in the prior year, the business earned $0.59 EPS. Equities research analysts anticipate that Crescent Capital BDC will post 2.43 earnings per share for the current fiscal year.

Institutional Trading of Crescent Capital BDC

A number of hedge funds and other institutional investors have recently modified their holdings of CCAP. Montag A & Associates Inc. bought a new position in Crescent Capital BDC in the fourth quarter valued at approximately $35,000. Van ECK Associates Corp grew its stake in shares of Crescent Capital BDC by 2.3% in the fourth quarter. Van ECK Associates Corp now owns 45,562 shares of the company's stock valued at $876,000 after buying an additional 1,006 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in Crescent Capital BDC by 11.9% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 105,343 shares of the company's stock worth $2,025,000 after buying an additional 11,161 shares during the last quarter. Redhawk Wealth Advisors Inc. bought a new position in shares of Crescent Capital BDC in the 4th quarter valued at about $659,000. Finally, Confluence Investment Management LLC increased its position in Crescent Capital BDC by 0.9% during the fourth quarter. Confluence Investment Management LLC now owns 73,839 shares of the company's stock worth $1,419,000 after buying an additional 633 shares during the last quarter. Institutional investors and hedge funds own 49.46% of the company's stock.

Crescent Capital BDC Company Profile

Crescent Capital BDC, Inc is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.